Live·Open questions in longevity research
Hypothesis Universe
Omega Point · Hypothesis

Clearance of dying cells may prolong life by resolving damaging

Young depleted of may improve survival through recipient clearing dying donor cells, without continued donor . Benefit persisting when donor death or recipient clearance is blocked would reject the proposed requirement.

Stage of verification

  1. Hypothesis published2026-10-03
  2. Indirect evidenceAssessed at 4 of 10
  3. Direct testAwaited

Map of the hypothesis

Hover over an icon or tap it to see its name.

Where in the body

Main connectionImmune system

Ageing mechanism

Main connectionChronic inflammation

Direction

Kind of knowledge gap

The question is designed to try to disprove the leading explanation.Adversarial gap

A double ring marks the main placement where a group contains several values.

Lens
Donor cell death and efferocytic resolution
Goal
Validated Menopause Syndrome Discovery and Durable Lifespan Intervention Protocol
Competing hypotheses
3
Published
2026-10-03
As a hypothesis
8 / 10Clarity of mechanism
8 / 10Few extra conditions
10 / 10Completeness of the answer
5 / 10Novelty of the idea
10 / 10Few new entities
8 / 10Decisive experiment
4 / 10Silver-bullet potential
4 / 10Support from research
Poster: Protocol Tests Ovarian-Cell Clearance
PosterOpen the sheet full size2026-10-04

Target map

Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.

  1. Specialised cell of an organ

    Non- of the ovary

    Where this hypothesis actsYoung donor depleted of

    Hypotheses on this target 3
    Ovarian somatic cellsFunction restoration. Hypotheses on this target 0Reprogramming. Hypotheses on this target 0Transplantation. Hypotheses on this target 22Elimination. Hypotheses on this target 11Proliferation. Hypotheses on this target 0
    • Function restoration
    • Reprogramming
    • Transplantation2
    • Elimination1
    • Proliferation

    What is proposed

    Elimination

    Induce controlled and clearance of donor cells

    With whatCell therapy

    HowManipulate donor and test a matched preparation of against ordinary and grafts

    Possible result

    Possible reduction in inflammatory mortality and functional deterioration

    From the recordThe graft's survival benefit requires controlled death and clearance of young ovarian somatic cells.

  2. Immune response

    The engulfment and clearance of cells by phagocytes

    Where this hypothesis actsRecipient encountering donor

    Hypotheses on this target 8
    EfferocytosisInhibition. Hypotheses on this target 55Activation. Hypotheses on this target 22Function preservation. Hypotheses on this target 0Clearance restoration. Hypotheses on this target 11Immunosuppression. Hypotheses on this target 0Feedback restoration. Hypotheses on this target 0Rhythm restoration. Hypotheses on this target 0
    • Inhibition5
    • Activation2
    • Function preservation
    • Clearance restoration1
    • Immunosuppression
    • Feedback restoration
    • Rhythm restoration

    What is proposed

    Activation

    Promote engulfment of donor cells by recipient

    With whatCell therapy

    HowProvide ; test dependence using a

    Possible result

    Possible sustained and improved survival and function

    From the recordRecipient macrophages engulf apoptotic donor cells and initiate sustained resolution of damaging inflammation; continued donor endocrine secretion is unnecessary.

All targets of the lab

Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.

MoleculesAntibodies. Hypotheses on this target 3AntibodiesInterleukin-1α. Hypotheses on this target 3Interleukin-1αAmyloid seeds. Hypotheses on this target 2Amyloid seedsATP. Hypotheses on this target 2ATPCGRP. Hypotheses on this target 2CGRPHyaluronan. Hypotheses on this target 2HyaluronanInterleukin-1 receptor antagonist. Hypotheses on this target 2Interleukin-1 receptor antagonistInterleukin-6. Hypotheses on this target 2Interleukin-6Potassium. Hypotheses on this target 2PotassiumSpecialized pro-resolving lipid mediators. Hypotheses on this target 2Specialized pro-resolving lipid mediatorsAmmonia. Hypotheses on this target 1AmmoniaAntimicrobial peptides. Hypotheses on this target 1Antimicrobial peptidesBlood carbon dioxide. Hypotheses on this target 1Blood carbon dioxideBMP. Hypotheses on this target 1BMPCholesterol crystals. Hypotheses on this target 1Cholesterol crystalsCorticosterone. Hypotheses on this target 1CorticosteroneCryptic collagen ligands. Hypotheses on this target 1Cryptic collagen ligandsDKK1. Hypotheses on this target 1DKK1Double-stranded RNA. Hypotheses on this target 1Double-stranded RNAExtracellular electrolytes. Hypotheses on this target 1Extracellular electrolytesExtracellular histones. Hypotheses on this target 1Extracellular histonesFas ligand. Hypotheses on this target 1Fas ligandGlutamine. Hypotheses on this target 1GlutamineGlutathione. Hypotheses on this target 1GlutathioneHeavy chain–hyaluronan complexes. Hypotheses on this target 1Heavy chain–hyaluronan complexesHistamine. Hypotheses on this target 1HistamineInterleukin-10. Hypotheses on this target 1Interleukin-10Interleukin-22. Hypotheses on this target 1Interleukin-22Lipid A. Hypotheses on this target 1Lipid ALipid hydroperoxides. Hypotheses on this target 1Lipid hydroperoxidesM3 receptor autoantibodies. Hypotheses on this target 1M3 receptor autoantibodiesNAD+. Hypotheses on this target 1NAD+NKG2D ligands. Hypotheses on this target 1NKG2D ligandsNoggin. Hypotheses on this target 1NogginOxygen. Hypotheses on this target 1OxygenPeroxide. Hypotheses on this target 1PeroxidePGP-family peptides. Hypotheses on this target 1PGP-family peptidesPhenol-soluble modulins alpha (PSMα). Hypotheses on this target 1Phenol-soluble modulins alpha (PSMα)Phosphatidylserine. Hypotheses on this target 1PhosphatidylserinePlatelet-activating anti-PF4 immunoglobulin. Hypotheses on this target 1Platelet-activating anti-PF4 immunoglobulinProstaglandin E2. Hypotheses on this target 1Prostaglandin E2RNA–DNA hybrids. Hypotheses on this target 1RNA–DNA hybridsSenescent-cell secretions. Hypotheses on this target 1Senescent-cell secretionsSmall RNAs. Hypotheses on this target 1Small RNAsSoluble BCMA. Hypotheses on this target 1Soluble BCMAStratum corneum lipids. Hypotheses on this target 1Stratum corneum lipidsTacrolimus. Hypotheses on this target 1TacrolimusTGF-β1. Hypotheses on this target 1TGF-β1Tissue-binding antibodies. Hypotheses on this target 1Tissue-binding antibodiesTryptophan. Hypotheses on this target 1TryptophanTumstatin. Hypotheses on this target 1TumstatinVIP. Hypotheses on this target 1VIPWNT. Hypotheses on this target 1WNT
GenesRetroelements. Hypotheses on this target 3RetroelementsAcquired nuclear DNA. Hypotheses on this target 1Acquired nuclear DNAAntimicrobial protein coding sequences. Hypotheses on this target 1Antimicrobial protein coding sequencesExtrachromosomal DNA. Hypotheses on this target 1Extrachromosomal DNAHerpes simplex virus genomes. Hypotheses on this target 1Herpes simplex virus genomesHLA-II expression. Hypotheses on this target 1HLA-II expressionHormone-response regulatory variant combinations. Hypotheses on this target 1Hormone-response regulatory variant combinationsIFT88. Hypotheses on this target 1IFT88IRF4 half-site CpG methylation at the TGFB1 enhancer. Hypotheses on this target 1IRF4 half-site CpG methylation at the TGFB1 enhancerUV photolesions. Hypotheses on this target 1UV photolesions
Enzymes and receptorsProteases. Hypotheses on this target 7ProteasesEP2 receptor. Hypotheses on this target 5EP2 receptorGLS1. Hypotheses on this target 5GLS1YAP. Hypotheses on this target 5YAPmTOR. Hypotheses on this target 4mTORERK. Hypotheses on this target 3ERKFAK. Hypotheses on this target 2FAKGlutamine synthetase. Hypotheses on this target 2Glutamine synthetasemTORC1. Hypotheses on this target 2mTORC1Myosin. Hypotheses on this target 2MyosinNK1 receptor. Hypotheses on this target 2NK1 receptorp300. Hypotheses on this target 2p30012-lipoxygenase. Hypotheses on this target 112-lipoxygenaseAcid sphingomyelinase. Hypotheses on this target 1Acid sphingomyelinaseACOD1. Hypotheses on this target 1ACOD1Acyloxyacyl hydrolase. Hypotheses on this target 1Acyloxyacyl hydrolaseADAR1. Hypotheses on this target 1ADAR1AKT. Hypotheses on this target 1AKTAlpha-adrenergic receptors. Hypotheses on this target 1Alpha-adrenergic receptorsAMPK. Hypotheses on this target 1AMPKAntiproteases. Hypotheses on this target 1AntiproteasesApoptotic caspases. Hypotheses on this target 1Apoptotic caspasesβ-arrestin-2. Hypotheses on this target 1β-arrestin-2CAD. Hypotheses on this target 1CADCatalase. Hypotheses on this target 1CatalaseCathepsins. Hypotheses on this target 1CathepsinsCD1a. Hypotheses on this target 1CD1aCD40. Hypotheses on this target 1CD40CD45. Hypotheses on this target 1CD45CD47. Hypotheses on this target 1CD47Collagen IV. Hypotheses on this target 1Collagen IVCollagen VII. Hypotheses on this target 1Collagen VIIDermal collagen I and III triple helices. Hypotheses on this target 1Dermal collagen I and III triple helicesDNA polymerase theta. Hypotheses on this target 1DNA polymerase thetaEGFR. Hypotheses on this target 1EGFReIF2α. Hypotheses on this target 1eIF2αExecutioner caspases. Hypotheses on this target 1Executioner caspasesFactor XIII. Hypotheses on this target 1Factor XIIIFcγRIIa. Hypotheses on this target 1FcγRIIaFibrin. Hypotheses on this target 1FibrinFibronectin. Hypotheses on this target 1FibronectinFilamin C. Hypotheses on this target 1Filamin CFKBP12. Hypotheses on this target 1FKBP12FPR2/ALX receptor. Hypotheses on this target 1FPR2/ALX receptorβ-glucocerebrosidase. Hypotheses on this target 1β-glucocerebrosidaseGlucose-6-phosphate dehydrogenase. Hypotheses on this target 1Glucose-6-phosphate dehydrogenaseHCMV Fc-binding proteins. Hypotheses on this target 1HCMV Fc-binding proteinsHistones. Hypotheses on this target 1HistonesHsp70. Hypotheses on this target 1Hsp70HSPB1. Hypotheses on this target 1HSPB1Hyaluronan synthase 2. Hypotheses on this target 1Hyaluronan synthase 2Interleukin-10 receptor. Hypotheses on this target 1Interleukin-10 receptorIntestinal alkaline phosphatase. Hypotheses on this target 1Intestinal alkaline phosphataseKCC2. Hypotheses on this target 1KCC2LOX. Hypotheses on this target 1LOXM3 muscarinic receptor. Hypotheses on this target 1M3 muscarinic receptorMast-cell chymase. Hypotheses on this target 1Mast-cell chymaseMetabolic enzymes. Hypotheses on this target 1Metabolic enzymesMYC. Hypotheses on this target 1MYCMyeloperoxidase. Hypotheses on this target 1MyeloperoxidaseN-homocysteinylated circulating fibrinogen. Hypotheses on this target 1N-homocysteinylated circulating fibrinogenNeutrophil elastase. Hypotheses on this target 1Neutrophil elastaseNitric oxide synthase. Hypotheses on this target 1Nitric oxide synthaseNK3 receptor. Hypotheses on this target 1NK3 receptorNKG2D receptor. Hypotheses on this target 1NKG2D receptorNOTUM. Hypotheses on this target 1NOTUMORF2. Hypotheses on this target 1ORF2PAR1. Hypotheses on this target 1PAR1PCMT1. Hypotheses on this target 1PCMT1PD-1. Hypotheses on this target 1PD-1PD-L1. Hypotheses on this target 1PD-L1Peptide–MHC complexes. Hypotheses on this target 1Peptide–MHC complexesPhosphofructokinase. Hypotheses on this target 1PhosphofructokinasePIEZO1. Hypotheses on this target 1PIEZO1Prostaglandin E2 receptors. Hypotheses on this target 1Prostaglandin E2 receptorsRibosomes. Hypotheses on this target 1RibosomesRNase H1. Hypotheses on this target 1RNase H1SIRT6. Hypotheses on this target 1SIRT6TIM-4. Hypotheses on this target 1TIM-4TLR2. Hypotheses on this target 1TLR2TRPV4. Hypotheses on this target 1TRPV4TSG-6. Hypotheses on this target 1TSG-6V8 protease. Hypotheses on this target 1V8 proteaseZAKα. Hypotheses on this target 1ZAKα
CellsSenescent fibroblasts. Hypotheses on this target 7Senescent fibroblastsSenescent cells. Hypotheses on this target 4Senescent cellsT cells. Hypotheses on this target 3T cellsCooperating dangerous cells in breast tissue. Hypotheses on this target 2Cooperating dangerous cells in breast tissueMacrophages. Hypotheses on this target 2MacrophagesSenescent stromal cells. Hypotheses on this target 2Senescent stromal cellsAdrenal zona fasciculata cells. Hypotheses on this target 1Adrenal zona fasciculata cellsAntigen-presenting cells. Hypotheses on this target 1Antigen-presenting cellsAPC-altered cells. Hypotheses on this target 1APC-altered cellsBasal cells. Hypotheses on this target 1Basal cellsCapillary mural cells. Hypotheses on this target 1Capillary mural cellsCD1a-reactive T cells. Hypotheses on this target 1CD1a-reactive T cellsCompeting cells. Hypotheses on this target 1Competing cellsCorticotrophs. Hypotheses on this target 1CorticotrophsDendritic cells. Hypotheses on this target 1Dendritic cellsDifferentiated cells. Hypotheses on this target 1Differentiated cellsDll1-positive secretory progenitors. Hypotheses on this target 1Dll1-positive secretory progenitorsEpithelial progenitor cells. Hypotheses on this target 1Epithelial progenitor cellsFibroadipogenic progenitor cells. Hypotheses on this target 1Fibroadipogenic progenitor cellsFibroblasts. Hypotheses on this target 1FibroblastsGroup 3 innate lymphoid cells. Hypotheses on this target 1Group 3 innate lymphoid cellsHepatocytes. Hypotheses on this target 1HepatocytesIntestinal epithelial cells. Hypotheses on this target 1Intestinal epithelial cellsLgr5-positive stem cells. Hypotheses on this target 1Lgr5-positive stem cellsMast cells. Hypotheses on this target 1Mast cellsMature absorptive epithelial cells. Hypotheses on this target 1Mature absorptive epithelial cellsMedullary thymic epithelial cells. Hypotheses on this target 1Medullary thymic epithelial cellsMesenchymal stromal cells. Hypotheses on this target 1Mesenchymal stromal cellsMyeloid-biased long-term hematopoietic stem cells. Hypotheses on this target 1Myeloid-biased long-term hematopoietic stem cellsMyeloid–tissue hybrid cells. Hypotheses on this target 1Myeloid–tissue hybrid cellsMyofibroblasts. Hypotheses on this target 1MyofibroblastsNeutrophils. Hypotheses on this target 1NeutrophilsNK cells. Hypotheses on this target 1NK cellsReparative cells. Hypotheses on this target 1Reparative cellsSenescent osteogenic cells. Hypotheses on this target 1Senescent osteogenic cellsStromal cells. Hypotheses on this target 1Stromal cellsThymic epithelial cells. Hypotheses on this target 1Thymic epithelial cellsTumor-reactive T cells. Hypotheses on this target 1Tumor-reactive T cellsOvarian somatic cells. Hypotheses on this target 3Ovarian somatic cells
Tissues and matrixExtracellular matrix. Hypotheses on this target 11Extracellular matrixCollagen fibers. Hypotheses on this target 6Collagen fibersSkin tissue. Hypotheses on this target 4Skin tissueElastin–fibrillin network. Hypotheses on this target 3Elastin–fibrillin networkSubcutaneous adipose tissue. Hypotheses on this target 2Subcutaneous adipose tissueAntigen deposits. Hypotheses on this target 1Antigen depositsArterial resistance. Hypotheses on this target 1Arterial resistanceBasement membranes. Hypotheses on this target 1Basement membranesCell neighborhood geometry. Hypotheses on this target 1Cell neighborhood geometryCell surface geometry. Hypotheses on this target 1Cell surface geometryCorneocyte intercellular contacts. Hypotheses on this target 1Corneocyte intercellular contactsEpidermal mechanical stress. Hypotheses on this target 1Epidermal mechanical stressHyaluronan-proteoglycan matrix. Hypotheses on this target 1Hyaluronan-proteoglycan matrixMechanical prestress. Hypotheses on this target 1Mechanical prestressMotor units. Hypotheses on this target 1Motor unitsSensory axons. Hypotheses on this target 1Sensory axonsStratum corneum. Hypotheses on this target 1Stratum corneumStromal contacts. Hypotheses on this target 1Stromal contactsTendon tissue. Hypotheses on this target 1Tendon tissueTissue compression. Hypotheses on this target 1Tissue compressionTissue hydrostatic pressure. Hypotheses on this target 1Tissue hydrostatic pressureTissue mechanical relaxation spectrum. Hypotheses on this target 1Tissue mechanical relaxation spectrumVenous capacitance. Hypotheses on this target 1Venous capacitanceWet contact network between skin, clothing and bedding. Hypotheses on this target 1Wet contact network between skin, clothing and bedding
ProcessesSensory afferent activity. Hypotheses on this target 7Sensory afferent activityEpithelial barrier repair. Hypotheses on this target 6Epithelial barrier repairLipid peroxidation. Hypotheses on this target 6Lipid peroxidationProtein translation. Hypotheses on this target 6Protein translationCalcium phosphate mineral growth. Hypotheses on this target 4Calcium phosphate mineral growthInflammation resolution. Hypotheses on this target 4Inflammation resolutionInflammatory response. Hypotheses on this target 4Inflammatory responseVasomotor discharges. Hypotheses on this target 4Vasomotor dischargesActomyosin contraction. Hypotheses on this target 3Actomyosin contractionAntigen-receptor signaling. Hypotheses on this target 3Antigen-receptor signalingAntimicrobial immune functions. Hypotheses on this target 3Antimicrobial immune functionsCircadian phase distribution. Hypotheses on this target 3Circadian phase distributionMemory replay. Hypotheses on this target 3Memory replayMitophagy. Hypotheses on this target 3MitophagyScope inference. Hypotheses on this target 3Scope inferenceSleep continuity. Hypotheses on this target 3Sleep continuityThermal balance. Hypotheses on this target 3Thermal balanceTissue renewal timing. Hypotheses on this target 3Tissue renewal timingAntigen presentation. Hypotheses on this target 2Antigen presentationAntimicrobial memory. Hypotheses on this target 2Antimicrobial memoryAutophagy. Hypotheses on this target 2AutophagyBacteriophage replication. Hypotheses on this target 2Bacteriophage replicationBlood flow–sweat secretion synchrony. Hypotheses on this target 2Blood flow–sweat secretion synchronyBone remodeling. Hypotheses on this target 2Bone remodelingCell fusion. Hypotheses on this target 2Cell fusionCell proliferation. Hypotheses on this target 2Cell proliferationCell recruitment. Hypotheses on this target 2Cell recruitmentEndocrine fluctuations. Hypotheses on this target 2Endocrine fluctuationsFerroptosis. Hypotheses on this target 2FerroptosisGap junction communication. Hypotheses on this target 2Gap junction communicationOxidative capacity. Hypotheses on this target 2Oxidative capacityPolyploidization. Hypotheses on this target 2PolyploidizationPositional signaling. Hypotheses on this target 2Positional signalingTransepithelial water transport. Hypotheses on this target 2Transepithelial water transportAct-to-training handoff. Hypotheses on this target 1Act-to-training handoffActivator–inhibitor signaling. Hypotheses on this target 1Activator–inhibitor signalingAnabolism. Hypotheses on this target 1AnabolismAntibody–effector co-occupancy. Hypotheses on this target 1Antibody–effector co-occupancyAntigen cross-presentation. Hypotheses on this target 1Antigen cross-presentationAntigen processing. Hypotheses on this target 1Antigen processingAntimicrobial deployment–epithelial repair synchrony. Hypotheses on this target 1Antimicrobial deployment–epithelial repair synchronyAttention allocation. Hypotheses on this target 1Attention allocationAutomatic recommendation delivery. Hypotheses on this target 1Automatic recommendation deliveryAutonomic recovery. Hypotheses on this target 1Autonomic recoveryBacterial utilization of exogenous fatty acids. Hypotheses on this target 1Bacterial utilization of exogenous fatty acidsCalcium homeostasis. Hypotheses on this target 1Calcium homeostasisCalcium signal decoding. Hypotheses on this target 1Calcium signal decodingCandidate/source binding. Hypotheses on this target 1Candidate/source bindingCardiovagal baroreflex. Hypotheses on this target 1Cardiovagal baroreflexCargo-mediated pathogen transfer. Hypotheses on this target 1Cargo-mediated pathogen transferCathelicidin carbamylation. Hypotheses on this target 1Cathelicidin carbamylationCausal test-selection policy. Hypotheses on this target 1Causal test-selection policyCell competition. Hypotheses on this target 1Cell competitionCell-cycle entry. Hypotheses on this target 1Cell-cycle entryCell membrane repair. Hypotheses on this target 1Cell membrane repairCell survival signaling. Hypotheses on this target 1Cell survival signalingCellular–antibody response timing. Hypotheses on this target 1Cellular–antibody response timingCentrosome organization. Hypotheses on this target 1Centrosome organizationcGAS–STING signaling. Hypotheses on this target 1cGAS–STING signalingChromatin programme of chronic secretion. Hypotheses on this target 1Chromatin programme of chronic secretionCoagulation cascade. Hypotheses on this target 1Coagulation cascadeCollagen crosslinking. Hypotheses on this target 1Collagen crosslinkingColonocyte metabolism. Hypotheses on this target 1Colonocyte metabolismCommunicative planning. Hypotheses on this target 1Communicative planningCommunity-conditioned modification of reconstruction. Hypotheses on this target 1Community-conditioned modification of reconstructionCompeting action accessibility. Hypotheses on this target 1Competing action accessibilityCompetitive drug displacement. Hypotheses on this target 1Competitive drug displacementComplement cascade. Hypotheses on this target 1Complement cascadeConcurrent incompatible-update reconciliation. Hypotheses on this target 1Concurrent incompatible-update reconciliationConvention compatibility. Hypotheses on this target 1Convention compatibilityCue-to-intention binding. Hypotheses on this target 1Cue-to-intention bindingCulture-to-risk feedback. Hypotheses on this target 1Culture-to-risk feedbackCutaneous vasodilation. Hypotheses on this target 1Cutaneous vasodilationDefault-preserving meta-choice. Hypotheses on this target 1Default-preserving meta-choiceDNA integration. Hypotheses on this target 1DNA integrationDNA repair. Hypotheses on this target 1DNA repairDNA replication licensing. Hypotheses on this target 1DNA replication licensingEnactment-cost feedback. Hypotheses on this target 1Enactment-cost feedbackEndocrine–circadian phase relationship. Hypotheses on this target 1Endocrine–circadian phase relationshipEndothelium-dependent vasodilation. Hypotheses on this target 1Endothelium-dependent vasodilationEntity correspondence. Hypotheses on this target 1Entity correspondenceEpidermal sealing–dermal remodeling synchrony. Hypotheses on this target 1Epidermal sealing–dermal remodeling synchronyEpidermal turnover. Hypotheses on this target 1Epidermal turnoverER-selective autophagy. Hypotheses on this target 1ER-selective autophagyErythrocyte arrival timing. Hypotheses on this target 1Erythrocyte arrival timingExcitation–secretion coupling. Hypotheses on this target 1Excitation–secretion couplingExtracellular infectious particle stabilization. Hypotheses on this target 1Extracellular infectious particle stabilizationExtracellular vesicle clearance. Hypotheses on this target 1Extracellular vesicle clearanceFailure detection and handover. Hypotheses on this target 1Failure detection and handoverFibrinolysis. Hypotheses on this target 1FibrinolysisGlutamine–glutamate cycle. Hypotheses on this target 1Glutamine–glutamate cycleGYS1-NONO condensation. Hypotheses on this target 1GYS1-NONO condensationHexosamine biosynthesis. Hypotheses on this target 1Hexosamine biosynthesisHistone export. Hypotheses on this target 1Histone exportHorizontal nuclear DNA transfer. Hypotheses on this target 1Horizontal nuclear DNA transferHost oxidant production. Hypotheses on this target 1Host oxidant productionIgG Fc glycosylation. Hypotheses on this target 1IgG Fc glycosylationImmune surveillance. Hypotheses on this target 1Immune surveillanceImmune target discrimination. Hypotheses on this target 1Immune target discriminationInstruction-scope conversion. Hypotheses on this target 1Instruction-scope conversionInterpretation switching. Hypotheses on this target 1Interpretation switchingIntracellular protein clearance. Hypotheses on this target 1Intracellular protein clearanceKeratinocyte polarity. Hypotheses on this target 1Keratinocyte polarityLymphocyte–APC contact timing. Hypotheses on this target 1Lymphocyte–APC contact timingLysosomal membrane permeabilization. Hypotheses on this target 1Lysosomal membrane permeabilizationLysosomal peptidoglycan degradation. Hypotheses on this target 1Lysosomal peptidoglycan degradationLysosome reformation. Hypotheses on this target 1Lysosome reformationMacromolecular crowding. Hypotheses on this target 1Macromolecular crowdingMeal–activity timing. Hypotheses on this target 1Meal–activity timingMechanical interference among lymphocytes. Hypotheses on this target 1Mechanical interference among lymphocytesMechanical load–mitosis timing. Hypotheses on this target 1Mechanical load–mitosis timingMechanical loading. Hypotheses on this target 1Mechanical loadingMechanoradical production. Hypotheses on this target 1Mechanoradical productionMental accounting. Hypotheses on this target 1Mental accountingMicrobial chemical defense. Hypotheses on this target 1Microbial chemical defenseMitochondrial fusion. Hypotheses on this target 1Mitochondrial fusionMitochondrial maintenance. Hypotheses on this target 1Mitochondrial maintenanceMitochondrial proton leak. Hypotheses on this target 1Mitochondrial proton leakMitochondrial transfer. Hypotheses on this target 1Mitochondrial transferMitosis. Hypotheses on this target 1MitosisMitotic entry in basal keratinocytes. Hypotheses on this target 1Mitotic entry in basal keratinocytesMitotic synchrony. Hypotheses on this target 1Mitotic synchronyMnemonic retention demand. Hypotheses on this target 1Mnemonic retention demandMuscle fiber adaptation. Hypotheses on this target 1Muscle fiber adaptationMutagenesis. Hypotheses on this target 1MutagenesisNeurogenic vasodilation. Hypotheses on this target 1Neurogenic vasodilationNeurokinin signaling. Hypotheses on this target 1Neurokinin signalingNeuronal secretion. Hypotheses on this target 1Neuronal secretionNF-κB activation. Hypotheses on this target 1NF-κB activationNitrogen-processing reaction network. Hypotheses on this target 1Nitrogen-processing reaction networkOrganelle maintenance. Hypotheses on this target 1Organelle maintenanceOxidative metabolism. Hypotheses on this target 1Oxidative metabolismParacrine signal–response synchrony. Hypotheses on this target 1Paracrine signal–response synchronyPartner retention and sorting. Hypotheses on this target 1Partner retention and sortingPathogen export. Hypotheses on this target 1Pathogen exportPeptide conjugation. Hypotheses on this target 1Peptide conjugationPeroxide clearance. Hypotheses on this target 1Peroxide clearancePlatelet adhesion. Hypotheses on this target 1Platelet adhesionPost-injury illness cascades. Hypotheses on this target 1Post-injury illness cascadesPreference construction. Hypotheses on this target 1Preference constructionPrimary cilium assembly. Hypotheses on this target 1Primary cilium assemblyProspective time allocation. Hypotheses on this target 1Prospective time allocationProtein carbamylation. Hypotheses on this target 1Protein carbamylationPublic commitment to cultural propositions. Hypotheses on this target 1Public commitment to cultural propositionsReceptor signal integration. Hypotheses on this target 1Receptor signal integrationReciprocal phase resetting. Hypotheses on this target 1Reciprocal phase resettingRegeneration–immune recognition timing. Hypotheses on this target 1Regeneration–immune recognition timingRegulatory-cell cytotoxicity. Hypotheses on this target 1Regulatory-cell cytotoxicityRelational memory. Hypotheses on this target 1Relational memoryRenal tubular reabsorption. Hypotheses on this target 1Renal tubular reabsorptionRibosome assembly. Hypotheses on this target 1Ribosome assemblyRNA splicing. Hypotheses on this target 1RNA splicingScratch contact. Hypotheses on this target 1Scratch contactScratch motor program. Hypotheses on this target 1Scratch motor programSemantic rewriting. Hypotheses on this target 1Semantic rewritingSensory integration. Hypotheses on this target 1Sensory integrationSkin adhesion. Hypotheses on this target 1Skin adhesionSkin barrier repair. Hypotheses on this target 1Skin barrier repairSolar radiation absorption. Hypotheses on this target 1Solar radiation absorptionSource-conditioned reconstruction. Hypotheses on this target 1Source-conditioned reconstructionSpatial coordination of ERK signaling. Hypotheses on this target 1Spatial coordination of ERK signalingStromal cell–matrix mechanical coupling. Hypotheses on this target 1Stromal cell–matrix mechanical couplingSweat evaporation. Hypotheses on this target 1Sweat evaporationThermoregulatory feedback. Hypotheses on this target 1Thermoregulatory feedbackTissue growth. Hypotheses on this target 1Tissue growthTissue renewal cycles. Hypotheses on this target 1Tissue renewal cyclesTissue repair. Hypotheses on this target 1Tissue repairTranscription. Hypotheses on this target 1TranscriptionTranscription-factor partnerships. Hypotheses on this target 1Transcription-factor partnershipsTranscription–replication conflicts. Hypotheses on this target 1Transcription–replication conflictsTranscriptional priming in estrogen-responsive cells. Hypotheses on this target 1Transcriptional priming in estrogen-responsive cellsTranscriptional repression. Hypotheses on this target 1Transcriptional repressionTransdermal drug absorption. Hypotheses on this target 1Transdermal drug absorptionTransmission timing. Hypotheses on this target 1Transmission timingtRNA queuosine modification. Hypotheses on this target 1tRNA queuosine modificationUbiquitin-dependent proteasomal degradation. Hypotheses on this target 1Ubiquitin-dependent proteasomal degradationVariant competition and selection. Hypotheses on this target 1Variant competition and selectionVascular obstruction. Hypotheses on this target 1Vascular obstructionEfferocytosis. Hypotheses on this target 8Efferocytosis
Microbial communitiesGut microbiota. Hypotheses on this target 3Gut microbiotaBacterial pathogens. Hypotheses on this target 1Bacterial pathogens
MeasurementsCultural transmission mechanism classification. Hypotheses on this target 9Cultural transmission mechanism classificationMenopause syndrome classification. Hypotheses on this target 5Menopause syndrome classificationSweat secretory response. Hypotheses on this target 5Sweat secretory responseCircadian phase. Hypotheses on this target 2Circadian phaseCognitive performance measurements. Hypotheses on this target 2Cognitive performance measurementsNyquist stability boundary. Hypotheses on this target 2Nyquist stability boundaryRecovery status classification. Hypotheses on this target 2Recovery status classificationAntibody neutralizing activity. Hypotheses on this target 1Antibody neutralizing activityApplied shear load. Hypotheses on this target 1Applied shear loadCausal-binding accessibility. Hypotheses on this target 1Causal-binding accessibilityClone size measurement. Hypotheses on this target 1Clone size measurementContractile exit assessment. Hypotheses on this target 1Contractile exit assessmentFunctional performance measurements. Hypotheses on this target 1Functional performance measurementsInvasion measurement. Hypotheses on this target 1Invasion measurementMitotically reactivatable infected cell count. Hypotheses on this target 1Mitotically reactivatable infected cell countmt-Keima signal. Hypotheses on this target 1mt-Keima signalOptical oxygen saturation estimate. Hypotheses on this target 1Optical oxygen saturation estimatePerfusion measurements. Hypotheses on this target 1Perfusion measurementsSemantic coding. Hypotheses on this target 1Semantic codingSkin ageing index. Hypotheses on this target 1Skin ageing indexSkin microdamage classification. Hypotheses on this target 1Skin microdamage classificationSkin redness. Hypotheses on this target 1Skin rednessSkin water evaporation measurement. Hypotheses on this target 1Skin water evaporation measurementTarget-specific immune response measurements. Hypotheses on this target 1Target-specific immune response measurementsTreatment response classification. Hypotheses on this target 1Treatment response classificationViable pathogen burden. Hypotheses on this target 1Viable pathogen burden

Solid and named: the targets of this hypothesis

Explore in depth

The logic

The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.

The descent, in plain words

Ovarian tissue might influence how long a recipient lives through more than its hormone production. The unexpected move is that a transplant could help because some donor cells die and are cleared away, rather than because those cells remain alive. This is a proposal generated by the pipeline, not a measured explanation of the reported survival benefit.

The proposed mechanism, link by link
  1. Removing egg-producing cells is proposed to make more dying accessible for clearance.
  2. Some transplanted undergo controlled cell death.
  3. Recipient engulf the dying donor cells.
  4. That engulfment is proposed to shift damaging into sustained resolution.
  5. Sustained resolution is proposed to reduce deaths associated with and slow loss of bodily function, without requiring continued donor hormone release.
A picture for it

The proposed transplant resembles a temporary delivery whose packaging triggers a lasting cleanup when it is collected. Keeping the packaging intact would prevent the cleanup signal, even though the delivery looked better preserved.

Where the picture breaks: Collecting dying cells is a biological interaction, not ordinary waste collection. The picture does not establish that ovarian cells trigger lasting protection, that clearance alone is sufficient, or that hormone release is dispensable.

  1. Master questionstep 01 of 04

    Patterns of symptoms and bodily changes associated with , the end of menstrual cycles, are proposed as a starting point for discovering ways to extend life substantially.

    Rests on: The goal treats changes surrounding the loss of ovarian reproductive function as potentially informative about processes that limit lifespan.

    Assumption

    It assumes that discovering -related patterns can reveal causes that can be changed to extend life substantially. The supplied material does not establish that connection.

  2. Goal pillarstep 02 of 04

    The intended outcome combines validated descriptions of -related conditions with an intervention whose effects on lifespan persist.

    Rests on: The master question explicitly connects discovery of -related conditions with substantial lifespan extension. This stage turns that ambition into a desired research outcome.

    Stated in the chain
  3. Gap questionstep 03 of 04

    The claimed survival advantage of young , transplanted ovarian tissue, is challenged by asking whether it survives controls for surgery, steroid hormone exposure, transplant survival and . The grafts in question lack , the cells that give rise to eggs, so the proposed remaining source of protection is , the other cells of the ovary.S2

    Rests on: The lifespan-intervention goal narrows to a reported ovarian transplant benefit. S2, a 2009 abstract in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, reports increased lifespan after young ovaries were transplanted into old mice, but does not establish the specific benefit or its proposed cause.

    Leap

    Neither the preceding goal nor the supplied source accounts establish the specific survival advantage of grafts that this question takes as its starting point. The chain also does not supply the connection from this transplant result to validated -related conditions.

  4. Hypothesisstep 04 of 04

    Controlled death and removal of donor ovarian cells are proposed to produce lasting relief from damaging , the body's injury and immune response. Recipient , immune cells that engulf cellular material, would clear donor cells undergoing , an orderly process of cell death. The predicted benefit therefore depends on donor-cell death rather than continued donor hormone release.

    Rests on: The preceding gap asks whether supply a distinct survival benefit after alternative explanations are controlled. This endpoint supplies a candidate explanation and an explicit distinguishing prediction: preventing donor-cell death should weaken protection even while improving transplant survival.

    Stated in the chain

What is carried, and what is not. None of the six supplied source accounts directly supports any of the five proposed mechanism links in the setting: S2 reports a mouse lifespan benefit without identifying this mechanism, while S1, in Annals of Biomedical Engineering in 2017, describes viable ovarian tissue and hormone function over 30 days without testing lifespan or donor-cell clearance. The remaining accounts provide background on ovarian transplantation or cell death, but none establishes the proposed sequence from dying donor cells to longer life.S2S1

Where the reasoning is carried by something unstated · 2
  • Master question. It assumes that discovering -related patterns can reveal causes that can be changed to extend life substantially. The supplied material does not establish that connection.
  • Gap question. Neither the preceding goal nor the supplied source accounts establish the specific survival advantage of grafts that this question takes as its starting point. The chain also does not supply the connection from this transplant result to validated -related conditions. Establish the missing link before relying on this step.
How a result here could mislead · 3
  • A loss of protection in grafts made resistant to cell death could reflect an accompanying change in hormone production or other released substances, rather than the absence of dying cells. What closes it: The specification requires verification that hormone production and other secretory functions remain comparable. Donor-cell tracking must also establish that the manipulation actually reduces donor-cell death while preserving transplant survival; equivalent surgery and alone do not settle this.
  • Blocking recipient-cell clearance could remove protection by harming the recipient generally, making that loss look like evidence that donor-cell engulfment is necessary. What closes it: The specified controls combine the clearance-blocking intervention with , the matched surgical procedure without the active transplant. Clearance measurements must verify that uptake of dying donor cells was reduced, and outcomes must be compared with these controls to distinguish general harm from loss of the proposed graft effect.
  • A short-term fall in could be read as lasting lifespan protection. Even longer survival could be credited to broad protection when it reflects fewer deaths from tumors, as one rival proposes. What closes it: The work requires long-term survival and bodily-function measurements rather than alone. Causes of death and tumor outcomes would also need assessment to distinguish reduced tumor mortality from the proposed sustained ; the supplied specification does not describe that assessment.

What would make this wrong. The proposed requirement for donor-cell death would be contradicted if grafts with verified suppression of that death retained the full long-term survival and functional benefit while hormone production and other secretory functions remained comparable. The requirement for recipient clearance would likewise be contradicted if protection persisted despite verified inhibition of donor-cell uptake. Failure of the dying-cell preparation alone would be ambiguous unless its intended delivery and uptake were established.

What it would change. If the predicted pattern held, ovarian transplantation research would have to treat donor-cell death and recipient clearance as possible causes of protection, alongside hormone production and transplant survival. -related lifespan research would then have a concrete candidate process to investigate beyond restoring ovarian hormone output. Even that result would not establish a syndrome, substantial lifespan extension in humans, or protection lasting across a human lifespan.

Sources read · 6

4 literature searches, 6 full texts, 4 abstract-only; 10 source(s) assessed against this question using the available text. A bounded search is not evidence of absence.

S1Background

Restoring Ovarian Endocrine Function with Encapsulated Ovarian Allograft in Immune Competent Mice. · Annals of biomedical engineering · 2017

“The ovarian tissue inside the device was viable, with no signs of necrosis and contained multiple follicles at different developmental stages.”

Does not settle: This source does not test lifespan or survival benefit, controlled donor-cell apoptosis, macrophage engulfment of apoptotic cells, sustained inflammatory resolution, germ-cell depletion, inflammatory mortality, functional deterioration, or whether preventing donor apoptosis weakens benefit. It examines ovarian graft viability and endocrine function over 30 days.

S2BackgroundAbstract only

Transplantation of young ovaries to old mice increased life span in transplant recipients. · The journals of gerontology. Series A, Biological sciences and medical sciences · 2009

“These results demonstrate that young ovaries enhanced longevity when transplanted to old mice and that ovarian status, examined by means of ovariectomy and ovarian transplantation, clearly influenced the potential of young transplanted ovaries to positively impact longevity.”

Does not settle: This abstract does not establish whether donor ovarian somatic-cell apoptosis or macrophage-mediated clearance is required, whether inflammation is resolved, whether endocrine secretion is unnecessary, whether germ-cell depletion alters apoptotic substrate, or whether preventing donor apoptosis weakens the survival benefit.

S4BackgroundAbstract only

Applications of ovarian tissue transplantation in experimental biology and medicine. · Human reproduction update · 2003

“After transplantation, follicular development and restoration of hormone secretion have been observed in animal and human studies.”

Does not settle: This abstract does not establish whether donor-cell apoptosis or macrophage clearance mediates any survival benefit, whether continued endocrine secretion is unnecessary, whether germ-cell depletion increases apoptotic substrate, or whether preventing donor apoptosis weakens longevity, inflammatory mortality, or functional outcomes.

S7Background

Ovarian Tissue Cryopreservation in Children and Adolescents. · Children (Basel, Switzerland) · 2022

“The recovery of endocrine function is observed in over 95% of cases, begins 2–9 months after grafting and holds its functionality even up to 7 years [ ].”

Does not settle: This source does not test lifespan or inflammatory mortality, donor-cell apoptosis or clearance, recipient macrophage engulfment, sustained inflammation resolution, germ-cell depletion, whether endocrine secretion is necessary for any survival benefit, or whether preventing donor apoptosis weakens benefit.

S9BackgroundAbstract only

The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. · Molecular and cellular endocrinology · 2002

“These observations suggest that the anti-inflammatory action of glucocorticoids is exerted by two complementary mechanisms: on the one hand, they induce death of the cells that provoke the inflammation, and on the other hand, they protect the resident cells of the inflamed tissue by arresting apoptotic signals.”

Does not settle: The source does not study ovarian grafts, apoptosis or clearance of donor ovarian somatic cells, recipient macrophage efferocytosis, germ-cell depletion, endocrine independence, graft viability, lifespan, inflammatory mortality, functional deterioration, or SPV_11.

S10Background

The role of caspase-8 in the tumor microenvironment of ovarian cancer. · Cancer metastasis reviews · 2021

“In normal ovaries, caspase-8 activation has been observed during the late luteal phase [ ].”

Does not settle: The source does not study ovarian grafts, donor-cell clearance, recipient macrophage efferocytosis, inflammation resolution, endocrine independence, germ-cell depletion, graft viability, lifespan, inflammatory mortality, functional deterioration, or whether preventing donor apoptosis weakens a graft benefit.

The gap this hypothesis explains

Two live hypotheses pull in opposite directions here, and the field has not chosen between them.

Does the survival benefit of young without egg-producing cells persist after accounting for surgery, hormones and graft health?

Original wording · exactly as the pipeline generated it
The gap question, as the engine wrote it

Does the reported survival advantage of young disappear when surgery, , and are controlled, falsifying a distinct ovarian somatic longevity signal?

What this question is asking

The question asks whether transplanted young ovarian tissue makes older female mice live longer because of a distinct signal from cells other than those that produce eggs. It concerns grafts depleted of , the cells that give rise to eggs, and asks whether their reported survival advantage remains when the comparison accounts for the operation, steroid hormone exposure, survival of the transplanted tissue and selection of recipient mice. The relevant comparison is survival after transplantation under conditions that separate these possible explanations. The question assumes that disappearance of the advantage under those controls would disprove a separate longevity signal from the remaining ovarian cells; that interpretation also needs scrutiny.

What the terms mean
Ovary and ovarian graft
An ovary is a reproductive organ containing egg-producing cells and other cells. An is ovarian tissue transplanted into a recipient; the question concerns tissue from young donors.
Germ cells and germ-cell depletion
are the cells that give rise to eggs in the ovary. Depletion means removing or reducing this cell population; the label alone does not establish how complete the removal was.
Ovarian somatic cells
These are the ovarian cells other than . The term covers multiple cell types rather than one uniform population, and the question proposes that some of them might influence lifespan.
Distinct ovarian somatic longevity signal
This is the proposed life-extending message or influence from ovarian cells other than , separate from the alternative explanations listed in the question. The supplied evidence does not identify a specific substance or establish that this separate effect exists.
Steroid hormone exposure and hormone replacement
are a class of chemical messages that includes hormones produced by ovaries. Exposure concerns how much hormone reaches the recipient and for how long; hormone replacement means restoring hormone activity that has declined or been lost.
Graft viability
This means whether the transplanted tissue remains alive and capable of functioning. A graft's survival is distinct from the lifespan of the animal receiving it.
Recipient selection and controlled comparison
is how animals are chosen for the groups being compared. A controlled comparison accounts for relevant differences between groups so that a survival difference is less likely to reflect those differences rather than the graft effect being examined.
Survival advantage and follow-up
A survival advantage means that one group lives longer than another according to the study's measurement. is the period during which outcomes are observed; in S1, the quoted percentage specifically compares time lived beyond surgery.
Prespecified threshold
This is a minimum required effect set before evaluating the result. The input requires such a threshold for survival benefit but does not supply its value.
Functional harm and excessive cell growth
Functional harm means loss of an ability or normal bodily function. Excessive cell growth refers to unwanted multiplication of cells; the input requires limits on these harms but supplies no numerical boundaries.
Tremor amplitude and grip strength
Tremor amplitude measures the size of involuntary shaking movements, while grip strength measures gripping force. S2 uses them to assess physical function, which does not directly measure lifespan.
Fertility and menopause
Fertility is the capacity to reproduce. is the permanent end of menstrual cycles associated with loss of ovarian reproductive function; the supplied mouse findings do not establish effects on human symptoms.
Falsification
Falsification means evidence contradicting a claim in a way that rules it out within its stated scope. Failure to retain one survival advantage would not automatically rule out every possible life-extending influence of ovarian cells.
What the question takes for granted
Premise only partly supported
Young depleted of have a reported survival advantage, and disappearance of that advantage after controlling surgery, , and would falsify a distinct ovarian somatic longevity signal.

The starting claim is that mice receiving young ovarian tissue without egg-producing cells have been reported to live longer than a comparison group. The additional assumption is that removing differences in the operation, hormones, transplanted tissue health and would provide a decisive test of a separate life-extending message from the remaining ovarian cells. If that assumption held, loss of the survival advantage would rule out that message as its explanation.

S1 supports a narrower claim: its abstract reports longer survival after surgery for mice receiving ovaries than for mice receiving ovaries containing . The supplied abstract does not establish whether the listed factors were adequately controlled. None of the supplied sources establishes that disappearance of the advantage would disprove the existence of a distinct signal; as a matter of inference, it would undermine the survival result as evidence for that signal under the conditions tested.S1

The same question asked without the part nothing read establishes:

  • Does the reported survival advantage of young depleted of egg-producing cells persist when surgery, steroid hormone exposure, graft health and are accounted for?
  • Do the supplied survival findings distinguish an effect of the remaining ovarian cells from an effect of hormone replacement?
What turns on the answer
  • The survival advantage disappears If accounting for the listed factors removes the survival difference, the original comparison would no longer support an additional longevity effect independent of those factors. That outcome would weaken the proposed explanation, but would not by itself identify which factor explained the original result or prove that no such signal exists.
  • The survival advantage persists If the survival difference remains after adequate control of the listed factors, those factors would not fully explain the benefit. A distinct signal from the remaining ovarian cells would remain a possible explanation, but its identity, mechanism and safety would still be unsettled.
  • The survival advantage becomes smaller A smaller remaining difference would indicate that the original advantage was at least partly dependent on the factors being accounted for. Whether the remainder meets the stated requirement would depend on its size and associated harms, neither of which is established for this comparison.
Why it matters

An introduces living tissue, and the question distinguishes a proposed longevity signal from effects of the operation, hormone exposure, graft health and differences between recipient mice. If those factors account for the survival difference, attributing it to a separate signal would misidentify the cause. If a difference remains after accounting for them, a distinct signal would remain a possible explanation, although the difference alone would not identify it. The stated requirement also includes a sufficiently large survival gain without unacceptable loss of function or excessive cell growth, so survival alone would not establish that the requirement has been met.

What is already established

RL-1 mouse graft findings suggest survival benefit but do not isolate or establish human relevance.

What would have to be true

An action-specific survival gain exceeds a over observed without unacceptable functional or .

What is missing

The strongest direct longevity lead could disappear under rigorous or be fully explained by ordinary .

The mechanism it proposes

The engine's own statement of the hypothesis, in full.

HERETICAL: The graft's survival benefit requires controlled death and clearance of young . Recipient engulf donor cells and initiate sustained ; continued donor is unnecessary. increases the accessible . Preventing donor should therefore weaken benefit despite improving . This mechanism stabilizes SPV_11 by reducing inflammatory mortality and functional deterioration.

Testing and possible results

The prediction that would tell it apart

A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.

Compare ordinary grafts, grafts, and a matched preparation of under equivalent surgery and . cells reproduce the survival and functional benefit, whereas lose it. A abolishes benefit, with the corresponding distinguishing general toxicity. transfer does not reproduce protection.

Would tell it apart from at least one rival. The prediction states observable differences in survival, functional benefit, and protection under specified comparisons and perturbations. No rival prediction is supplied. Only a bench experiment would settle it.

What testing it would take

The engine's own read on whether this is testable with methods that already exist.

, manipulation and support an initial . donors require verification that steroid production and other secretory functions remain comparable. Long-term benefit cannot be inferred from short-term reduction.

Other explanations

Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.

This hypothesis predicts

Compare ordinary grafts, grafts, and a matched preparation of under equivalent surgery and . cells reproduce the survival and functional benefit, whereas lose it. A abolishes benefit, with the corresponding distinguishing general toxicity. transfer does not reproduce protection.

  • What would separate them

    Young ovarian networks may limit systemic injury by rejecting isolated extreme distress signals predicts: In a , one versus several independently connected while matching total exposure. A functioning young ovarian network rejects a single extreme input but responds to concordant distributed inputs. Selectively disabling input sensing while preserving abolishes this pattern. Only after demonstrating that signature should grafted animals test whether sensing-competent grafts outperform sensing-disabled grafts and a matched in survival and function.

  • What would separate them

    Ovarian graft antigens could trigger tumor immunity and extend survival predicts: Protection transfers with purified recipient , but not with after removal of donor-derived material. Removing an experimentally identified shared from otherwise matched donor tissue, or selectively interrupting its , eliminates the survival advantage. Benefit is concentrated in reduced lethal tumors; broad functional recovery is not required. Equal and clearance of donor cells fail to reproduce protection.

  • What would separate them

    Small genetic messages from young ovarian support cells may suppress mobile genetic elements predicts: Identify a donor-derived that reaches recipient at an effective concentration. Selectively remove that from donor cells while preserving viability, , and major protein secretion. Loss of recipient and survival benefit, followed by with but not a version, supports this IH. Recipient with should escape suppression despite otherwise intact graft signaling.

Why this is not the mainstream account

The engine is asked to say what its hypothesis would overturn and what would surprise a specialist. This is its answer.

Empirical anchor

reportedly extended survival and reduced , leaving the active somatic contribution unresolved: [ study](https://pubmed.ncbi.nlm.nih.gov/30547325/). In a separate transplantation setting, donor and recipient were necessary for : [Galleu et al.](https://pubmed.ncbi.nlm.nih.gov/29141887/). Neither study establishes this ovarian mechanism.

Subfield revised

; the textbook chapter topic is 'Graft survival, and mechanisms of transplant benefit.' Confirmation would replace viable young somatic secretion as the necessary agent with donor destruction and recipient-mediated resolution.

Testable surprise

A nonviable ovarian preparation outperforms a healthier, longer-surviving in observed survival, while blocking donor eliminates benefit.

Why this is not the mainstream account

The targeted search did not identify a review proposing this mechanism for lifespan extension. Absolute absence cannot be proved. -dependent therapeutic activity is already established for , so the heretical claim is specifically that viability is to , not that is novel.

What stands behind it

Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.

This hypothesis states no figure and cites no study, so there is nothing here to trace.

CitationsCites nothingFiguresnone statedPredictionWould tell it apart from at least one rivalTo refuteOnly a bench experiment would settle it

What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.

0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.